Denileukin diftitox: a novel immunotoxin

@article{Manoukian2009DenileukinDA,
  title={Denileukin diftitox: a novel immunotoxin},
  author={George Manoukian and Fredrick B. Hagemeister},
  journal={Expert Opinion on Biological Therapy},
  year={2009},
  volume={9},
  pages={1445 - 1451}
}
Objective: To review FDA approved and other potential uses of Ontak, denileukin diftitox. Methods: Information was obtained via the internet and a journal literature review. Results: In 1999, the FDA approved the use of denileukin diftitox for patients with persistent or relapsed CD25-positive cutaneous T-cell lymphoma (CTCL), but Ontak has been reported to be an effective therapy for other neoplastic and non-neoplastic conditions. Oncological uses include therapy for CD25-negative T-cell… 
Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
TLDR
Denileukin diftitox (DD) is unique among CTCL therapies in that it is a genetically engineered fusion protein that combines the cytotoxic and membrane translocating domains of the diphtheria toxin with a truncated sequence of human IL-2 that is internalized and blocks protein synthesis.
Potential breakthroughs with investigational drugs for hairy cell leukemia
TLDR
This article summarizes recent investigational therapies of HCL, looking at their mechanism of action, pharmacological properties, clinical activity and toxicity, as well as their emerging role in its treatment.
The IL-2 Diphtheria Toxin Fusion Protein Denileukin Diftitox Modulates the Onset of Diabetes in Female Nonobese Diabetic Animals in a Time-Dependent Manner and Breaks Tolerance in Male Nonobese Diabetic Animals
TLDR
It is demonstrated that the injection of denileukin diftitox leads to a dramatic development of type 1 diabetes within days after injection, thereby obviously breaking pre-existing tolerance mechanisms.
Immunotoxins in cancer therapy: Review and update
TLDR
The advantages and limitations of bacterial toxinssuch as Pseudomonas and Diphtheria toxins, plant toxins such as ricin and gelonin, and some endogenous protein of human origin such as RNases and Granzymes are discussed.
Interleukin-2 Receptor Targeted Therapy of Ocular Disease of HTLV-1-associated Adult T-cell Leukemia
TLDR
Scleritis in patients with underlying HTLV-1-associated ATL is responsive to IL-2 receptor targeted therapies, and improvement in scleritis was noted in both patients.
ANTIBODY DERIVATIVES AS NEW THERAPEUTICS FOR HEMATOLOGIC MALIGNANCIES Immunotoxins for leukemia
A growing number of monoclonal antibodies (mAbs) have been approved for the treatment of hematologic malignancies. Newer constructs have been designed to improve activity, for example, through the
Utility of BCL2, PD1, and CD25 Immunohistochemical Expression in the Diagnosis of T-cell Lymphomas
TLDR
Compared the expression of the CD25, PD-1, and bcl-2 in 119 cases of T-cell non-Hodgkin lymphoma using immunohistochemical techniques applied to routinely processed and paraffin-embedded tissues, it is shown that lack of expression of b cl-2 was observed in 52% of TCL and may aid in identification of neoplastic T- cell populations.
Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
TLDR
Small modular immunopharmaceuticals that retain Fc-mediated effector functions have been developed and investigated in preclinical studies and clinical trials and will elucidate the role of these agents in the treatment of CLL.
Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms
TLDR
The antibody-drug conjugate (ADC) is a unique combination of potent cytotoxic drugs covalently linked to monoclonal antibodies (mAb) through a stable specialized chemical linker that maximizes drug delivery to tumor cells without increasing toxicity to normal cells.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Denileukin diftitox: a concise clinical review
TLDR
The clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma are reviewed, and the potential future role of this novel drug in patients with both malignant and nonmalignant diseases is discussed.
DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
TLDR
Data from the phase I trial suggest that the definition of activity in other cancer types, including other non-Hodgkin's lymphomas (NHL), is warranted, and the potential to target the high-affinity IL-2R supports the development of this agent in transplantation and in autoimmune diseases.
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
  • N. Dang, F. Hagemeister, L. Fayad
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Denileukin diftitox seems to be effective in relapsed or refractory, CD25+ and CD25- B-cell NHL and is well-tolerated at the dosage evaluated.
DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date.
TLDR
A review of the efficacy and toxicity trials with DAB(389)IL-2 completed to date in cancer, in particular those that involved patients with cutaneous T-cell lymphoma, as well as the rationale for these trials.
Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease.
  • P. Shaughnessy, C. Bachier, C. LeMaistre
  • Medicine, Biology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2005
A phase II study of denileukin diftitox (ONTAK) in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia
TLDR
A phase II study to evaluate the efficacy and toxicity of ONTAK in patients with fludarabine-refractory CLL and the overall response was 27%, with 1 CR.
Phase II study of denileukin diftitox for previously treated low grade non-Hodgkin’s lymphoma: E1497 final report
TLDR
This phase II trial was designed to evaluate the response rate (RR) and toxicity of DD in pts with relapsed low grade B-cell NHL, and to evaluate RR by tumor interleukin-2 receptor (IL-2R) expression.
Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma.
TLDR
Clinical improvement of myelofibrosis and acute T-cell leukemia after denileukin diftitox administration is demonstrated, suggesting that denileUKin diftsitox may affect the paracrine secretion of HTLV-1-associated clinical manifestations of ATL.
Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma
TLDR
This study examined the ability of a fusion protein of interleukin-2 (IL-2) and diphtheria toxin (Denileukin Diftitox) to eliminate regulatory T lymphocytes based on their expression of high-affinity IL-2 receptors and found that the increased numbers of lymphocytes in patients resulting from treatment with IL-1 were not susceptible to Denileuk in DIFTitox.
DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
  • F. Foss
  • Biology, Medicine
    Clinical lymphoma
  • 2000
TLDR
DAB(389)IL-2 (denileukin diftitox; ONTAK), with a unique mechanism of action, is the first genetically constructed fusion protein to reach the clinic and has shown clinical activity in a variety of diseases, including B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphoma, Hodgkin's disease, psoriasis, rheumatoid arthritis, and HIV infection.
...
1
2
3
4
5
...